SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten
A Former Cyber Spy Raised $30 Million For A Security Startup. Plus: These Are The Richest Women In The World forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM , the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy , at the 73rd Annual.
/PRNewswire/ Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology.
New analysis of the REDUCE-IT trial suggested benefit of icosapent ethyl doesn't vary by Lp(a) level and confirmed risk for Lp(a) with high triglycerides but not cholesterol.